TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06499311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Description: Foot Reflexology is an alternative medical practice involving the application of pressure to specific points on the feet. It has been reported as a non-invasive complementary therapy that was addressed as an effective technique that is reported to reduce premenstrual symptoms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure is a sort of massage therapy, was addressed as an effective technique that is reported to reduce premenstrual symptoms. Acupressure is a well-known form of Traditional Chinese Medicine that is a component of alternative treatments.
Study: NCT05124028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: 50mg po qd 6 weeks
Study: NCT05833854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses group
Description: It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual pressure group
Description: In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
Study: NCT05043506

Intervention type: DRUG
Intervention: Palbociclib + aromatase inhibitor
Description: Palbociclib + an aromatase inhibitor therapy

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor monotherapy
Study: NCT05037708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Description: Subjects are randomly assigned to group 1. Group 1 receives treatment A\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B\*\* was applied to group 1 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymphatic drainage
Description: Subjects are randomly assigned to group 2. Group 2 receives treatment B\*\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A\* was applied to group 2 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment
Study: NCT05812898

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercises
Description: strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: myofascial release using instrument assisted soft tissue mobilization
Study: NCT06384768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video training
Description: A 4 week support program consist of videos for fear of childbirth
Study: NCT04737356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
Study: NCT04761575

Intervention type: OTHER
Intervention: Validation of the FFQ65+ via eNutri app
Description: All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
Study: NCT04861506

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
Study: NCT05804071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Description: Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Description: Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Description: Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Description: Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Description: Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions
Study: NCT05544201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-definition transcranial current stimulation
Description: High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial current stimulation
Description: High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-definition transcranial current stimulation
Description: High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
Study: NCT04884386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted gait training
Description: RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional locomotion therapy
Description: locomotion exercise, postural control training, balance training, electrotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional locomotion therapy
Description: locomotion exercise, postural control training, balance training, electrotherapy
Study: NCT05856929

Intervention type: OTHER
Intervention: no Intervention
Description: no intervention
Study: NCT05699239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172 10mg bid
Description: oral administration of TS-172 10 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172 30mg bid
Description: oral administration of TS-172 30 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172 60mg bid
Description: oral administration of TS-172 60 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172 20mg tid
Description: oral administration of TS-172 20 mg tid
Study: NCT04984070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives, Combined
Description: One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
Study: NCT05699239

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo
Study: NCT05256888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: 12 weeks of time-restricted eating (10-hour window)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy lifestyle education
Description: Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle education
Description: Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
Study: NCT06474000

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin induction group
Description: Participants in the oxytocin induction group filled out the Information Form at the time of application to the delivery room. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in the control group filled in the Information Form when they applied to the birth centre. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure.
Study: NCT05754398

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: six independent and interconnected educational training sessions
Description: Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach.
Study: NCT06428669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitro-Bid 2 % Topical Ointment
Description: Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
Study: NCT05393258

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: temporally-modulated pulsed radiotherapy (TMPRT)
Description: Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
Study: NCT05214456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
Study: NCT05081167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: REL-1017 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT05989750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scaler
Description: Ultrasonic scaling for subgingival cleaning every 6 months for 2 years according to the manufacturer's procedures.
Study: NCT06277947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)
Description: The C-HIPEC would be performed at bedside in the general ward within 24 hours after surgery. The HIPEC treatment instruments are BR-TRG-II system, which can control the temperature stably to 43℃±0.1℃.
Study: NCT06552975

Intervention type: OTHER
Intervention: Infection
Description: Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.

Intervention type: OTHER
Intervention: Infection
Description: Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
Study: NCT05895877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goofice®
Description: Once daily before breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goofice® Placebo
Description: Once daily before breakfast.
Study: NCT05989750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Flow Prophylaxis Master
Description: AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning according to the manufacturer's procedures.
Study: NCT04984070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Pill
Description: Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
Study: NCT05387031

Intervention type: DRUG
Intervention: Ustekinumab
Description: The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
Study: NCT05012488

Intervention type: OTHER
Intervention: Comparison of gait and foot pressure
Description: The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
Study: NCT04984070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
Study: NCT06135922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-TCR-T cells
Description: The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.
Study: NCT05099341

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HDRS-17 depression scale
Description: Measuring the severity of depression
Study: NCT05726955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: an exercise training program applied with conservative treatment and a stretching platform (ETSP) 3 days a week for 6 weeks
Study: NCT04812769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCARE-ID
Description: The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care will be delivered to the control home.
Study: NCT05984511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: I-125 Seeds Brachytherapy in PVTT
Description: Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab plus Bevacizumab
Description: Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Description: Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
Study: NCT05099341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HDRS-17 depression scale
Description: Measuring the severity of depression
Study: NCT05297383

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Polyunsaturated Fatty Acid.
Description: 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Polyunsaturated Fatty Acid.
Description: 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: 4 grams safflower oil (AlaskOmega®) per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: 4 grams safflower oil (AlaskOmega®) per day.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High-Intensity Interval Training
Description: A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Training
Description: A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Flexibility Training
Description: 30 min of stretching 3 days/week for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: 30 min of stretching 3 days/week for 6 weeks
Study: NCT06451055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-calorie diet
Description: LCD diet is designed to provide \~1300 kcal/day with a macronutrient composition of 55% carbohydrate, 13% fat, 25% protein, and 2% fiber.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine dietary and physical activity habits
Description: Participants will be asked to maintain their habitual dietary and physical activity habits.
Study: NCT06139198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans
Description: SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
Study: NCT05591430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ganglion Impar Neurolysis
Description: block of Ganglion Impar by neurolytic drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral S2, S3 and S4 Pulsed radiofrequency
Description: Bilateral S2, S3 and S4 Pulsed radiofrequency